STOCK TITAN

SOPHiA GENETICS SA Ordinary Shares - SOPH STOCK NEWS

Welcome to our dedicated page for SOPHiA GENETICS SA Ordinary Shares news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on SOPHiA GENETICS SA Ordinary Shares stock.

SOPHiA GENETICS SA (Nasdaq: SOPH) is a leader in the field of data-driven medicine, leveraging cutting-edge technology to advance healthcare. Based in Switzerland, the company is renowned for its high medical standards and precision. SOPHiA GENETICS has built the SOPHiA DDM™ Platform, a cloud-based SaaS platform designed to analyze complex genomic and multimodal data, delivering valuable insights for clinical and life sciences research.

Through its innovative platform, SOPHiA GENETICS supports healthcare professionals in over 100 hospitals globally, enabling them to perform faster and more accurate diagnoses using next-generation sequencing (NGS) analytics. The platform also facilitates knowledge sharing within the largest clinical genomics community.

Recently, SOPHiA GENETICS has made significant strides with several notable partnerships:

  • Unilabs, a prominent European diagnostic provider, adopted the SOPHiA DDM™ Platform to enhance their HRD-status testing capabilities in solid tumors.
  • Syndicate Bio in Nigeria integrated MSK-ACCESS® powered by SOPHiA DDM™, marking the first comprehensive genomic profiling and liquid biopsy availability across Africa.
  • Klinikum Klagenfurt in Austria and Instituto Mário Penna in Brazil have also implemented the platform to advance their cancer diagnostics and treatment planning, particularly in blood-related cancers and disorders.

Financially, SOPHiA GENETICS is recognized for its robust operational execution and business momentum, continually reaffirming its guidance. The company is actively collaborating with tech giants like Microsoft and NVIDIA to develop a streamlined whole genome sequencing (WGS) analytical solution, promising rapid and precise insights aiding clinical decision-making.

SOPHiA GENETICS also launched SOPHiA UNITY, a global consortium to accelerate cancer research by harnessing diverse, high-quality data from leading institutions worldwide. The platform’s advanced AI-based technology and proprietary algorithms will support decision-making and expedite oncology research.

For more information, visit SOPHiAGENETICS.com or connect on LinkedIn, X, Facebook, and Instagram.

Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) announced its participation in two upcoming investor conferences. The company will hold a fireside chat at the Evercore ISI HealthCONx Virtual Conference on November 29 at 2:15 PM EST and at the Credit Suisse 26th Annual Technology Conference on November 30 at 1:40 PM MST. Live and archived webcasts can be accessed through the Investor Relations section of their website. SOPHiA GENETICS focuses on data-driven medicine through its SOPHiA DDM™ Platform, serving numerous healthcare institutions globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
conferences
-
Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) has announced a multi-year strategic partnership with Microsoft on Nov. 1, 2022, to enhance healthcare workflows globally through its SOPHiA DDM™ health data analysis platform, powered by Microsoft Azure. This collaboration aims to break down data silos and facilitate multimodal data curation, improving clinical outcomes and patient care. The partnership will enable healthcare providers to deliver precision medicine more effectively, leveraging AI and machine learning technologies to generate actionable insights for improved health outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
partnership
-
Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) will release its Q3 fiscal 2022 financial results on November 8, 2022, before U.S. markets open. The company plans to host a conference call at 8:30 a.m. EST to discuss these results and its business outlook. Investors can access the call via the SOPHiA GENETICS Investor Relations website, where a replay will be available afterward. The firm focuses on data-driven medicine, offering the SOPHiA DDM™ Platform used by various healthcare institutions globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
Rhea-AI Summary

SOPHiA GENETICS, a cloud-native software company focused on data-driven medicine, hosted its inaugural Investor Day in New York on September 20, 2022. Major highlights included a memorandum of understanding with Memorial Sloan Kettering Cancer Center to enhance cancer genomics and a partnership with Boundless Bio for developing precision oncology therapies targeting extrachromosomal DNA in oncogene amplified cancers. The event showcased SOPHiA's CarePath solution, which leverages real-world data and aims to transform patient care and research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.45%
Tags
none
-
Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) hosted its inaugural Investor Day in New York City on September 20, 2022. The event featured key presentations from executive leaders discussing the company's growth strategies and unique differentiators in the healthcare technology space. Attendees included the board chairman, CEO, and various chief officers, aiming to enhance investor understanding of SOPHiA's data-driven medicine approach. The event was open to registered participants and provided a webcast option for broader access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
-
Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) announced that CEO Dr. Jurgi Camblong and CFO Ross Muken will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference. This event will take place on September 12, 2022, at 8:45 a.m. EDT. SOPHiA GENETICS is a cloud-native software company focused on data-driven medicine, utilizing its SOPHiA DDM™ Platform for analyzing complex multimodal data sets. Its solutions are widely used by hospitals, laboratories, and biopharma institutions globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2022 revenue of $11.7 million, a 15% increase from Q2 2021. Excluding COVID-19 revenues, constant currency growth was 36%. Gross margin improved to 65%, with a record adjusted gross margin of 67%. However, operating loss widened to $24.1 million, up from $15.9 million year-over-year. The company maintained its revenue growth guidance for FY 2022 at 30% to 35%, though overall revenue is now expected between $47 million and $49.5 million due to currency fluctuations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.08%
Tags
-
Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) has announced its inaugural Investor Day scheduled for September 20, 2022, at PUBLIC Hotel in New York City. The event will commence at 1:30 p.m. EDT and conclude by approximately 5:30 p.m. EDT. Presentations will be made by CEO Dr. Jurgi Camblong and the executive leadership team, followed by a Q&A session and reception. Due to limited capacity, registration is required. The event will also be available via live webcast, with replays accessible the next day.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.64%
Tags
conferences
-
Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) announced that CFO Ross Muken will participate as a panelist at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, in Boston, MA. Muken will join other industry leaders for the panel titled “Leveraging Omics-Based Data and Analytics to Advance Precision Health to the Next Level”, starting at 9:30 a.m. EST. A live webcast and replay will be available on the company's investor relations website.

More than 790 institutions globally utilize the SOPHiA DDM™ Platform, which analyzes complex multimodal data for healthcare advancements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
conferences
Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) will announce its financial results for Q2 2022 on August 9, 2022, before U.S. markets open. The company will host a conference call at 8:30 a.m. EDT to discuss these results and the business outlook. The conference call will be available for live streaming on their Investor Relations website, with a replay to follow. SOPHiA GENETICS is focused on data-driven medicine and serves over 790 institutions globally with its SOPHiA DDM™ Platform, which analyzes multimodal data for healthcare and research purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.85%
Tags

FAQ

What is the current stock price of SOPHiA GENETICS SA Ordinary Shares (SOPH)?

The current stock price of SOPHiA GENETICS SA Ordinary Shares (SOPH) is $3.65 as of November 1, 2024.

What is the market cap of SOPHiA GENETICS SA Ordinary Shares (SOPH)?

The market cap of SOPHiA GENETICS SA Ordinary Shares (SOPH) is approximately 241.9M.

What does SOPHiA GENETICS do?

SOPHiA GENETICS is a healthcare technology company that leverages AI to analyze complex genomic and multimodal data, providing insights for clinical diagnostics and life sciences research.

What is the SOPHiA DDM™ Platform?

The SOPHiA DDM™ Platform is a cloud-based SaaS solution that analyzes next-generation sequencing (NGS) data and integrates various diagnostic modalities to deliver actionable insights for healthcare providers.

Where is SOPHiA GENETICS based?

SOPHiA GENETICS is headquartered in Switzerland, with a physical presence in France, the United States, and Brazil.

Who are some of SOPHiA GENETICS' partners?

Recent partners include Unilabs in Europe, Syndicate Bio in Nigeria, Klinikum Klagenfurt in Austria, and Instituto Mário Penna in Brazil.

What is SOPHiA UNITY?

SOPHiA UNITY is a data-driven consortium designed to accelerate cancer research globally by bringing together healthcare institutions to share and analyze diverse, high-quality data.

How does SOPHiA GENETICS support precision medicine?

Through its SOPHiA DDM™ Platform, SOPHiA GENETICS enables healthcare providers to perform fast, accurate genetic analyses, facilitating data-driven treatment decisions and advancing precision medicine.

What recent advancements have SOPHiA GENETICS made?

Recent advancements include the integration of their platform by Unilabs for HRD-testing in tumors, the launch of WGS solutions in collaboration with Microsoft and NVIDIA, and the formation of SOPHiA UNITY for cancer research.

What is the company's mission?

SOPHiA GENETICS' mission is to expand access to data-driven medicine globally, using AI to provide world-class care to patients with cancer and rare disorders.

How does SOPHiA GENETICS ensure data privacy and quality?

The company employs advanced bioinformatics and machine learning technologies to ensure high-quality analysis and secure banking of patient DNA sequence data, maintaining stringent privacy standards.

How can I learn more about SOPHiA GENETICS?

For more information, visit their website at SOPHiAGENETICS.com or connect with them on social media platforms like LinkedIn, X, Facebook, and Instagram.

SOPHiA GENETICS SA Ordinary Shares

Nasdaq:SOPH

SOPH Rankings

SOPH Stock Data

241.89M
65.38M
5.84%
49.85%
0.02%
Health Information Services
Healthcare
Link
United States of America
Rolle